Cargando…
Cancer-associated thrombosis: prevention and treatment
Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in s...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216419/ https://www.ncbi.nlm.nih.gov/pubmed/18231650 |
_version_ | 1782149144351080448 |
---|---|
author | Brose, K.M.J. Lee, A.Y.Y. |
author_facet | Brose, K.M.J. Lee, A.Y.Y. |
author_sort | Brose, K.M.J. |
collection | PubMed |
description | Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent evidence on the prevention and treatment of venous thromboembolism in cancer patients is presented here. |
format | Text |
id | pubmed-2216419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-22164192008-01-29 Cancer-associated thrombosis: prevention and treatment Brose, K.M.J. Lee, A.Y.Y. Curr Oncol Medical Oncology Patients with cancer are at high risk to develop venous thromboembolism, and they are also more likely to develop complications from anticoagulant treatment. Because little research has focused on the oncology population to date, the optimal methods of prophylaxis and treatment remain uncertain in some clinical situations. Currently, low molecular weight heparin and warfarin are the most frequently used pharmacologic agents; however, they have their limitations. Other therapeutic options, such as inferior caval filters, are poorly studied and remain controversial. A summary of the most recent evidence on the prevention and treatment of venous thromboembolism in cancer patients is presented here. Multimed Inc. 2008-01 /pmc/articles/PMC2216419/ /pubmed/18231650 Text en 2008 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Medical Oncology Brose, K.M.J. Lee, A.Y.Y. Cancer-associated thrombosis: prevention and treatment |
title | Cancer-associated thrombosis: prevention and treatment |
title_full | Cancer-associated thrombosis: prevention and treatment |
title_fullStr | Cancer-associated thrombosis: prevention and treatment |
title_full_unstemmed | Cancer-associated thrombosis: prevention and treatment |
title_short | Cancer-associated thrombosis: prevention and treatment |
title_sort | cancer-associated thrombosis: prevention and treatment |
topic | Medical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2216419/ https://www.ncbi.nlm.nih.gov/pubmed/18231650 |
work_keys_str_mv | AT brosekmj cancerassociatedthrombosispreventionandtreatment AT leeayy cancerassociatedthrombosispreventionandtreatment |